...Trevor C.I. Wilkinson The development of recombinant antibody therapeutics is a significant area of growth in the pharmaceutical industry with almost 50 approved monoclonal antibodies on the market in the US and Europe. Despite this growth, however, certain classes of important molecular targets...

... Biochemical Society 2011 central nervous system dystroglycan glycosylation monoclonal antibody muscular dystrophy DG (dystroglycan) is an essential component of the DGC (dystrophin-associated glycoprotein complex) that links the muscle cell cytoskeleton to the extracellular matrix [ 1...

...A. Melnick DLBCL (diffuse large B-cell lymphoma) is the most common subtype of non-Hodgkin's lymphoma. Current therapy for patients includes chemotherapy and monoclonal antibodies. Although oncogene-targeted therapy is dramatically successful for patients with certain kinds of leukaemias...

...R. Juliano The use of macromolecules, particularly monoclonal antibodies, as therapeutic agents has come to the forefront in recent years. The biodistribution and delivery issues for protein drugs are shared to a substantial degree with other emerging therapeutic approaches including...